Since 09/2020 | Head of AG Immunotherapy Robert Bosch Cancer Centre, Stuttgart and Senior physician CCU Translational Immunology, University Hospital Tübingen |
Since 07/2020 | Head of the “Wirkstoffpeptidlabor”, Department of Immunology, University of Tübingen |
09/2019 - 08/2020 | Senior physician CCU Translational Immunology/Department of Hematology and Oncology |
04/2019 - 08/2019 | Research scholarship, National Institute of Health (NIH), lab of Prof. Tim Greten, Bethesda, USA |
05/2018 | Habilitation (internal medicine) at the Medical Faculty, Eberhard Karls University Tübingen |
05/2017 - 03/2019 | Specialist for internal medicine and hematology and oncology at the University Hospital Tübingen, Medical Department II |
Since 01/2012 | Research group leader Department of Immunology, University Tübingen „Peptide-based immunotherapy“ |
04/2011 | Medical dissertation MD, summa cum laude |
2011 - 2017 | Residency at the University Hospital Tübingen, Medical Department II |
2004 - 2010 | Medical school, Eberhard Karls University Tübingen |
2020 | Poster Award of the University Tübingen, research colloquium |
2018 | Poster Award DGHO Wien |
2017 | Poster Award of the University Tübingen, research colloquium |
2016 | Young Investigator Award DGHO Leipzig |
2015 | Württembergischer Krebspreis, junior award |
2015 | Poster Award DGHO Basel |
2014 | Abstract Achievement Award American Society of Hematology |
2013 | Abstract Achievement Award American Society of Hematology |
2012 | Abstract Achievement Award American Society of Hematology |
2011 | Ludolf Krehl Award of the Süddeutschen Gesellschaft für Innere Medizin |
2011 | Dissertation award of the Eberhard Karls University Tübingen |
2020 | CoVac-1 peptide cocktail: PCT/EP 20 190 070.1 |
2020 | SARS-CoV-2 CD8+ und CD4+ T cell epitopes: PCT/EP 20 169 047.6 |
2018 | Peptides and combination thereof for use in the immunotherapy against cancers: PCT/EP2018/059109 |
2018 | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers: PCT/EP2018/059114 |
2016 | Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers: PCT/EP2016/064317 |
2014 | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)” Priority application: UK Nr. 1411037.3 und US 62/014,849 |
2014 | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) Priority application: UK Nr. 1408255.6 und US 61/990,980 |